SETTING: Multidrug-resistant tuberculosis patients without human immunodeficiency virus (HIV) infection, with Mycobacterium tuberculosis resistant to almost all of the available drugs. OBJECTIVE: Limited phase II trial with recombinant interferon-alpha2b in five chronic multidrug-resistant tuberculosis patients. METHODS: Three million units of r-IFN-alpha2b were administered subcutaneously every week for 12 weeks. Before and after treatment, and during a 30-month follow-up period, the patients underwent clinical and radiological examination, together with bacteriological, immunological and routine laboratory testing. RESULTS: Two of the five patients became long-term sputum smear and culture negative after r-IFN-alpha2b therapy; one of the patients showed clinical improvement and negative smear after therapy, but remained culture positive. The other two patients showed no response. CONCLUSION: The results of this trial suggest that r-IFN-alpha2b should be evaluated further in multidrug-resistant tuberculosis in prospective controlled trials.
SETTING: Multidrug-resistant tuberculosis patients without human immunodeficiency virus (HIV) infection, with Mycobacterium tuberculosis resistant to almost all of the available drugs. OBJECTIVE: Limited phase II trial with recombinant interferon-alpha2b in five chronic multidrug-resistant tuberculosis patients. METHODS: Three million units of r-IFN-alpha2b were administered subcutaneously every week for 12 weeks. Before and after treatment, and during a 30-month follow-up period, the patients underwent clinical and radiological examination, together with bacteriological, immunological and routine laboratory testing. RESULTS: Two of the five patients became long-term sputum smear and culture negative after r-IFN-alpha2b therapy; one of the patients showed clinical improvement and negative smear after therapy, but remained culture positive. The other two patients showed no response. CONCLUSION: The results of this trial suggest that r-IFN-alpha2b should be evaluated further in multidrug-resistant tuberculosis in prospective controlled trials.
Authors: M Lichtner; R Rossi; F Mengoni; S Vignoli; B Colacchia; A P Massetti; I Kamga; A Hosmalin; V Vullo; C M Mastroianni Journal: Clin Exp Immunol Date: 2006-02 Impact factor: 4.330
Authors: Daimon P Simmons; David H Canaday; Yi Liu; Qing Li; Alex Huang; W Henry Boom; Clifford V Harding Journal: J Immunol Date: 2010-07-21 Impact factor: 5.422
Authors: Jeffrey A Gold; Yoshihiko Hoshino; Satomi Hoshino; Marcus B Jones; Anna Nolan; Michael D Weiden Journal: Infect Immun Date: 2004-03 Impact factor: 3.441
Authors: Gregory S Olson; Tara A Murray; Ana N Jahn; Dat Mai; Alan H Diercks; Elizabeth S Gold; Alan Aderem Journal: Cell Rep Date: 2021-06-01 Impact factor: 9.423
Authors: Jeffrey A Gold; Yoshihiko Hoshino; Marcus B Jones; Satomi Hoshino; Anna Nolan; Michael D Weiden Journal: PLoS One Date: 2007-08-15 Impact factor: 3.240